M42 and Uzbekistan’s Ministry of Health signed a Memorandum of Understanding (MoU) to collaborate and explore opportunities for strategic partnerships on the Uzbek Genome Programme.
The agreement, signed during the visit of the President of Uzbekistan, Shavkat Mirziyoyev, to the UAE, marks the ambition of the Abu Dhabi-based global health tech major’s ambition to expand its foothold in genomics and grow its contribution to global genomics diversity.
The partnership aims to collaborate in the fields of genomics, next-generation prevention, novel screening, and diagnostics development in the Republic of Uzbekistan.
The projects under the pact include developing in-country genomics capabilities to enable an Uzbek Genome Programme, designing, developing and manufacturing locally and regionally relevant, scalable screening and diagnostic tools and supporting the research, development, manufacturing and export of ‘made in Uzbekistan’ novel screening and diagnostics.
“Through this strategic partnership with M42, we are not only advancing the potential of our national healthcare system but also contributing to global efforts to explore genetic diversity, said Farhkodjon Tashpulatov, Uzbekistan’s Deputy Minister of Health.
“Special attention will be given to training our specialists and integrating advanced technologies, positioning Uzbekistan as a leader in genomics in Central Asia,” he added.
Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer at M42 and Chairman of Cleveland Clinic Abu Dhabi, said the company’s partnership with Uzbekistan’s Ministry of Health is transformational for Uzbekistan’s healthcare ecosystem, for the Uzbek people and for global diversity in genomics research.
“With the lack of diversity in genomic research, underrepresented populations in the world are having to go without critical benefits ranging from advanced clinical care to early detection of diseases and rational drug design,” he said.
Follow us on
